Royalty Pharma (RPRX) Financials

$33.09 -1.16 (-3.39%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Royalty Pharma

This table shows Royalty Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	859	1,135	43	620	975	2,349	1,378
Consolidated Net Income / (Loss)	1,331	1,700	230	1,241	1,702	2,461	1,518
Net Income / (Loss) Continuing Operations	1,331	1,700	230	1,241	1,702	2,461	1,518
Total Pre-Tax Income	1,331	1,700	230	1,241	1,702	2,461	1,518
Total Operating Income	1,292	1,492	307	1,431	1,595	2,623	1,364
Total Gross Profit	2,264	2,355	2,237	2,289	2,122	1,814	1,795
Total Revenue	2,264	2,355	2,237	2,289	2,122	1,814	1,795
Operating Revenue	2,264	2,355	2,237	2,289	2,122	1,814	1,795
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	971	862	1,930	859	527	-809	430
Selling, General & Admin Expense	237	250	227	183	182	103	62
Research & Development Expense	2.00	52	177	200	26	83	393
Amortization Expense	0.00	0.00	5.67	23	23	24	33
Other Operating Expenses / (Income)	732	561	904	453	231	-1,019	-57
Impairment Charge	0.00	0.00	616	0.00	65	-	-
Total Other Income / (Expense), net	38	208	-77	-190	107	-162	153
Interest Expense	226	187	188	166	157	269	280
Interest & Investment Income	77	101	69	34	73	-10	17
Other Income / (Expense), net	187	294	42	-57	191	117	416
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	472	565	187	621	727	113	140
Basic Earnings per Share	$1.92	$2.54	$0.10	$1.49	$1.32	$0.00	$0.00
Weighted Average Basic Shares Outstanding	448.19M	447.60M	437.96M	414.79M	375.44M	0.00	0.00
Diluted Earnings per Share	$1.91	$2.53	$0.10	$1.49	$1.32	$0.00	$0.00
Weighted Average Diluted Shares Outstanding	594.11M	602.90M	437.97M	414.80M	375.46M	0.00	0.00
Weighted Average Basic & Diluted Shares Outstanding	576.45M	597.43M	607.22M	607.18M	607.11M	-	-
Cash Dividends to Common per Share	$0.84	$0.80	$0.76	$0.68	$0.15	-	-

This table shows Royalty Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	238	208	544	102	4.78	494	72	228	341	-456	143
Consolidated Net Income / (Loss)	433	334	806	194	-4.27	718	122	351	509	-610	220
Net Income / (Loss) Continuing Operations	433	334	806	194	-4.27	718	122	351	509	-610	220
Total Pre-Tax Income	433	334	806	194	-4.27	718	122	351	509	-610	220
Total Operating Income	534	362	735	270	-74	613	151	249	479	-483	192
Total Gross Profit	568	594	565	537	568	596	536	538	684	566	573
Total Revenue	568	594	565	537	568	596	536	538	684	566	573
Operating Revenue	568	594	565	537	568	596	536	538	684	566	573
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	34	232	-170	268	642	-17	385	289	205	1,048	381
Selling, General & Admin Expense	111	68	57	55	58	59	57	48	86	73	51
Research & Development Expense	51	0.50	0.50	0.50	0.50	0.50	51	0.50	0.50	51	26
Other Operating Expenses / (Income)	-127	164	-228	212	584	-77	277	241	119	309	305
Total Other Income / (Expense), net	-101	-27	71	-75	70	105	-29	102	30	-127	28
Interest Expense	65	66	67	49	44	47	46	47	47	47	47
Interest & Investment Income	18	41	28	15	-6.73	6.77	18	25	51	37	11
Other Income / (Expense), net	-53	-2.09	110	-41	120	145	-1.55	125	26	-117	64
Income Tax Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	195	126	262	92	-9.05	223	50	124	168	-154	78
Basic Earnings per Share	$0.55	$0.46	$1.22	$0.23	$0.01	$1.11	$0.16	$0.51	$0.76	($1.04)	$0.32
Weighted Average Basic Shares Outstanding	435.48M	448.19M	447.63M	451.02M	448.62M	447.60M	448.44M	450.41M	445.61M	437.96M	439.29M
Diluted Earnings per Share	$0.55	$0.46	$1.21	$0.23	$0.01	$1.11	$0.16	$0.50	$0.76	($1.04)	$0.32
Weighted Average Diluted Shares Outstanding	578.10M	594.11M	592.73M	596.91M	597.48M	602.90M	601.14M	605.86M	607.25M	437.97M	607.23M
Weighted Average Basic & Diluted Shares Outstanding	562.24M	576.45M	589.18M	593.46M	597.44M	597.43M	597.43M	601.82M	607.14M	607.22M	607.22M

This table details how cash moves in and out of Royalty Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	452	-1,234	170	532	762	-1,678	543
Net Cash From Operating Activities	2,769	2,988	2,144	2,018	2,035	1,667	1,618
Net Cash From Continuing Operating Activities	2,769	2,988	2,144	2,014	2,027	1,647	1,618
Net Income / (Loss) Continuing Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	2,769	2,988	2,144	2,014	2,035	1,647	1,615
Net Cash From Investing Activities	-2,678	-2,073	-1,029	-1,870	-2,759	-2,154	303
Net Cash From Continuing Investing Activities	-2,678	-2,073	-1,029	-1,870	-2,759	-2,154	303
Acquisitions	-11	-13	-9.90	-35	-40	-27	-24
Purchase of Investments	-2,736	-2,116	-2,565	-3,594	-3,938	-2,743	-422
Sale and/or Maturity of Investments	43	70	1,334	1,777	834	875	750
Other Investing Activities, net	26	-14	211	-19	385	-259	0.00
Net Cash From Financing Activities	361	-2,149	-945	385	1,487	-1,192	-1,379
Net Cash From Continuing Financing Activities	361	-2,154	-945	385	1,487	-1,192	-1,379
Repayment of Debt	-22	-1,352	-1.35	-13	-11,257	-294	-296
Repurchase of Common Equity	-230	-305	0.00	0.00	-	-4.27	0.00
Payment of Dividends	-864	-855	-951	-919	-1,123	-893	-1,083
Issuance of Debt	1,471	350	0.00	1,273	11,891	0.00	0.00
Other Financing Activities, net	5.11	7.48	7.19	44	67	0.00	0.00

This table details how cash moves in and out of Royalty Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	159	-21	-815	922	366	-459	-1,237	197	265	719	-1,116
Net Cash From Operating Activities	596	743	704	658	665	773	574	608	1,034	570	539
Net Cash From Continuing Operating Activities	584	743	704	665	658	773	574	608	1,034	580	532
Net Income / (Loss) Continuing Operations	0.00	-	-	-	0.00	-	-	-	0.00	-	-
Non-Cash Adjustments To Reconcile Net Income	584	743	704	665	658	773	574	608	1,034	580	532
Net Cash From Investing Activities	504	-506	-1,193	-893	-87	-1,000	-451	-63	-559	415	-1,425
Net Cash From Continuing Investing Activities	504	-506	-1,193	-893	-87	-1,000	-451	-63	-559	415	-1,425
Acquisitions	0.00	-	-	-3.98	-6.97	-1.99	-3.98	-2.99	-3.58	-	-6.85
Purchase of Investments	-5.48	-496	-1,207	-947	-86	-1,002	-451	-60	-602	-361	-1,631
Sale and/or Maturity of Investments	559	-83	113	6.82	6.41	6.10	4.46	-	59	565	213
Other Investing Activities, net	-50	74	-99	51	0.00	-2.04	-	-	-12	211	-
Net Cash From Financing Activities	-941	-258	-326	1,157	-212	-232	-1,359	-347	-210	-266	-230
Net Cash From Continuing Financing Activities	-941	-539	-224	1,336	-212	-522	-1,259	-163	-210	-266	-230
Repurchase of Common Equity	-709	-53	-97	-	-	-30	-140	-	-	-	-
Payment of Dividends	-234	-487	-125	-38	-213	-491	-121	-29	-214	-266	-232
Other Financing Activities, net	1.30	1.25	1.26	1.17	1.43	1.11	1.75	1.03	3.59	1.35	1.86
Cash Interest Received	12	-	-	-	6.43	-	-	-	-	-	7.29

This table presents Royalty Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	18,223	16,382	16,813	17,516	16,020	12,450
Total Current Assets	1,802	1,274	2,555	2,878	2,697	832
Cash & Equivalents	929	477	1,711	1,541	1,009	246
Short-Term Investments	58	18	26	648	1,053	94
Note & Lease Receivable	784	738	691	614	587	453
Other Current Assets	31	40	127	75	48	39
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	16,421	15,108	14,259	14,638	13,323	11,618
Long-Term Investments	1,073	813	623	640	618	255
Noncurrent Note & Lease Receivables	15,127	14,089	13,493	13,718	12,368	10,842
Other Noncurrent Operating Assets	220	206	142	274	309	469
Total Liabilities & Shareholders' Equity	18,223	16,382	16,813	17,516	16,020	12,450
Total Liabilities	7,880	6,298	7,288	7,267	6,124	6,308
Total Current Liabilities	1,254	161	1,167	171	308	333
Short-Term Debt	998	0.00	998	0.00	-	282
Accounts Payable	13	15	7.91	114	137	42
Other Current Liabilities	144	95	107	0.00	19	9.22
Other Current Nonoperating Liabilities	98	52	54	58	42	0.00
Total Noncurrent Liabilities	6,627	6,136	6,121	7,096	5,817	5,975
Long-Term Debt	6,615	6,135	6,119	7,096	5,817	5,956
Other Noncurrent Operating Liabilities	12	0.90	2.50	0.00	-	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	10,342	10,084	9,525	10,249	9,896	6,141
Total Preferred & Common Equity	6,947	6,526	5,628	5,777	4,819	2,823
Total Common Equity	6,947	6,526	5,628	5,777	4,819	2,823
Common Stock	4,104	4,012	3,666	3,508	2,866	0.00
Retained Earnings	2,846	2,518	1,965	2,255	1,921	2,825
Treasury Stock	-2.66	-2.63	-2.81	-2.72	-2.32	-4.27
Other Equity Adjustments	0.00	0.00	0.00	0.00	0.00	0.00
Noncontrolling Interest	3,396	3,558	3,897	4,472	5,077	3,318

This table presents Royalty Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	17,608	18,042	17,657	16,131	15,856	17,121	17,074	17,673
Total Current Assets	1,843	1,794	2,579	1,560	1,729	2,954	2,631	2,342
Cash & Equivalents	1,088	950	1,765	843	936	2,173	1,976	992
Short-Term Investments	12	49	39	29	5.30	5.10	2.50	549
Note & Lease Receivable	717	766	750	660	742	730	610	676
Other Current Assets	27	30	26	27	45	45	43	125
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	15,765	16,248	15,077	14,571	14,127	14,168	14,443	15,330
Long-Term Investments	555	1,008	982	824	732	728	652	750
Noncurrent Note & Lease Receivables	15,032	14,968	13,890	13,465	13,230	13,268	13,662	14,287
Other Noncurrent Operating Assets	178	272	206	282	165	172	130	293
Total Liabilities & Shareholders' Equity	17,608	18,042	17,657	16,131	15,856	17,121	17,074	17,673
Total Liabilities	7,820	7,784	7,905	6,267	6,270	7,308	7,252	7,256
Total Current Liabilities	1,183	1,168	276	125	128	1,172	1,117	1,132
Short-Term Debt	999	997	-	-	0.00	999	998	997
Accounts Payable	38	22	23	12	14	5.81	105	122
Other Current Liabilities	127	110	196	100	102	113	0.00	-
Other Current Nonoperating Liabilities	19	38	56	13	13	54	13	13
Total Noncurrent Liabilities	6,637	6,616	7,629	6,143	6,142	6,136	6,135	6,125
Long-Term Debt	6,619	6,610	7,602	6,139	6,131	6,127	6,123	6,115
Other Noncurrent Operating Liabilities	18	5.58	27	3.22	11	8.50	12	9.90
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9,789	10,258	9,752	9,864	9,585	9,814	9,822	10,416
Total Preferred & Common Equity	6,689	6,870	6,476	6,500	6,139	6,282	5,954	6,152
Total Common Equity	6,689	6,870	6,476	6,500	6,139	6,282	5,954	6,152
Common Stock	4,211	4,108	4,101	4,075	4,007	4,031	3,740	3,633
Retained Earnings	2,481	2,765	2,378	2,427	2,135	2,253	2,217	2,505
Treasury Stock	-2.65	-2.66	-2.66	-2.65	-2.62	-2.63	-2.83	-2.79
Other Equity Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Noncontrolling Interest	3,100	3,389	3,276	3,364	3,446	3,532	3,868	4,264

This table displays calculated financial ratios and metrics derived from Royalty Pharma's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	-3.86%	5.24%	-2.28%	7.87%	16.98%	1.08%	0.00%
EBITDA Growth	-17.17%	404.07%	-74.62%	-22.82%	-34.55%	52.40%	0.00%
EBIT Growth	-17.17%	412.27%	-74.61%	-23.12%	-34.82%	53.91%	0.00%
NOPAT Growth	-13.38%	385.94%	-78.54%	-10.32%	-39.18%	92.25%	0.00%
Net Income Growth	-21.72%	638.96%	-81.46%	-27.07%	-30.85%	62.16%	0.00%
EPS Growth	-24.51%	2,430.00%	-93.29%	12.88%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-7.32%	39.36%	6.27%	-0.84%	22.04%	3.02%	0.00%
Free Cash Flow Firm Growth	-69.63%	58.81%	898.38%	-122.42%	103.32%	0.00%	0.00%
Invested Capital Growth	6.88%	4.37%	-1.63%	11.46%	10.96%	0.00%	0.00%
Revenue Q/Q Growth	-0.11%	1.30%	-0.44%	0.16%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-21.23%	317.36%	-67.44%	-14.91%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-21.23%	317.36%	-67.62%	-15.13%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-16.28%	276.24%	-67.44%	-10.09%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-22.36%	356.43%	-74.26%	-20.14%	0.00%	0.00%	0.00%
EPS Q/Q Growth	-25.39%	565.79%	-91.15%	-23.20%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-1.08%	7.28%	3.87%	-3.62%	4.48%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	188.06%	-45.65%	32.36%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.60%	6.46%	-6.00%	-0.99%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	65.36%	75.86%	15.84%	60.99%	85.25%	152.35%	101.05%
Operating Margin	57.10%	63.37%	13.73%	62.49%	75.17%	144.59%	76.02%
EBIT Margin	65.36%	75.86%	15.58%	59.98%	84.16%	151.04%	99.19%
Profit (Net Income) Margin	58.79%	72.20%	10.28%	54.21%	80.19%	135.67%	84.57%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	89.96%	95.18%	65.98%	90.38%	95.28%	89.83%	85.25%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	8.35%	10.19%	2.12%	10.35%	12.84%	44.52%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	9.08%	14.48%	0.44%	5.30%	15.25%	38.79%	0.00%
Return on Net Nonoperating Assets (RNNOA)	4.68%	7.15%	0.20%	1.97%	8.39%	35.64%	0.00%
Return on Equity (ROE)	13.03%	17.34%	2.33%	12.32%	21.23%	80.16%	0.00%
Cash Return on Invested Capital (CROIC)	1.70%	5.91%	3.77%	-0.49%	2.45%	-155.48%	0.00%
Operating Return on Assets (OROA)	8.55%	10.76%	2.03%	8.19%	12.55%	22.01%	0.00%
Return on Assets (ROA)	7.69%	10.24%	1.34%	7.40%	11.96%	19.77%	0.00%
Return on Common Equity (ROCE)	8.59%	10.75%	1.34%	6.48%	10.11%	36.85%	0.00%
Return on Equity Simple (ROE_SIMPLE)	19.16%	26.05%	4.09%	21.49%	35.32%	87.19%	0.00%
Net Operating Profit after Tax (NOPAT)	1,292	1,492	307	1,431	1,595	2,623	1,364
NOPAT Margin	57.10%	63.37%	13.73%	62.49%	75.17%	144.59%	76.02%
Net Nonoperating Expense Percent (NNEP)	-0.73%	-4.29%	1.69%	5.05%	-2.42%	5.73%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	7.20%	9.20%	1.85%	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	10.46%	10.61%	10.16%	7.99%	8.56%	5.70%	3.45%
R&D to Revenue	0.09%	2.21%	7.92%	8.74%	1.24%	4.58%	21.87%
Operating Expenses to Revenue	42.90%	36.63%	86.27%	37.51%	24.83%	-44.59%	23.98%
Earnings before Interest and Taxes (EBIT)	1,479	1,786	349	1,373	1,786	2,740	1,780
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,479	1,786	354	1,396	1,809	2,764	1,814
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.16	2.49	4.03	3.92	3.71	0.66	0.00
Price to Tangible Book Value (P/TBV)	2.16	2.49	4.03	3.92	3.74	0.67	0.00
Price to Revenue (P/Rev)	6.64	6.91	10.14	9.89	8.43	1.02	1.03
Price to Earnings (P/E)	17.50	14.34	529.67	36.55	18.35	0.79	1.35
Dividend Yield	3.29%	2.94%	2.03%	1.82%	0.65%	0.00%	0.00%
Earnings Yield	5.72%	6.97%	0.19%	2.74%	5.45%	126.61%	74.27%
Enterprise Value to Invested Capital (EV/IC)	1.50	1.65	2.19	2.15	2.00	0.92	0.00
Enterprise Value to Revenue (EV/Rev)	10.59	10.47	14.01	13.71	12.30	5.96	0.00
Enterprise Value to EBITDA (EV/EBITDA)	16.21	13.81	88.45	22.48	14.43	3.91	0.00
Enterprise Value to EBIT (EV/EBIT)	16.21	13.81	89.89	22.86	14.62	3.95	0.00
Enterprise Value to NOPAT (EV/NOPAT)	18.55	16.53	102.07	21.94	16.36	4.12	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	8.66	8.25	14.62	15.56	12.83	6.49	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	91.28	28.51	57.53	0.00	85.79	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.74	0.61	0.75	0.69	0.59	1.02	0.00
Long-Term Debt to Equity	0.64	0.61	0.64	0.69	0.59	0.97	0.00
Financial Leverage	0.52	0.49	0.46	0.37	0.55	0.92	0.00
Leverage Ratio	1.69	1.69	1.74	1.66	1.78	2.03	0.00
Compound Leverage Factor	1.52	1.61	1.15	1.50	1.69	1.82	0.00
Debt to Total Capital	42.40%	37.83%	42.76%	40.91%	37.02%	50.39%	0.00%
Short-Term Debt to Total Capital	5.56%	0.00%	5.99%	0.00%	0.00%	2.28%	0.00%
Long-Term Debt to Total Capital	36.84%	37.83%	36.77%	40.91%	37.02%	48.11%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	18.91%	21.94%	23.42%	25.78%	32.31%	26.81%	0.00%
Common Equity to Total Capital	38.69%	40.24%	33.82%	33.30%	30.67%	22.80%	0.00%
Debt to EBITDA	5.15	3.44	20.08	5.08	3.21	2.26	0.00
Net Debt to EBITDA	3.75	2.70	13.42	3.06	1.73	2.04	0.00
Long-Term Debt to EBITDA	4.47	3.44	17.27	5.08	3.21	2.15	0.00
Debt to NOPAT	5.89	4.11	23.18	4.96	3.65	2.38	0.00
Net Debt to NOPAT	4.30	3.23	15.49	2.98	1.97	2.15	0.00
Long-Term Debt to NOPAT	5.12	4.11	19.93	4.96	3.65	2.27	0.00
Altman Z-Score	1.79	2.35	2.33	2.63	2.60	1.41	0.00
Noncontrolling Interest Sharing Ratio	34.04%	38.02%	42.32%	47.40%	52.35%	54.03%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	1.44	7.90	2.19	16.81	8.76	2.50	0.00
Quick Ratio	1.41	7.65	2.08	16.37	8.60	2.38	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	263	865	545	-68	304	-9,160	0.00
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	1.16	4.62	2.90	-0.41	1.94	-34.11	0.00
Operating Cash Flow to Interest Expense	12.28	15.96	11.41	12.14	12.95	6.21	5.78
Operating Cash Flow Less CapEx to Interest Expense	12.28	15.96	11.41	12.14	12.95	6.21	5.78
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.13	0.14	0.13	0.14	0.15	0.15	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	15,993	14,963	14,336	14,574	13,075	11,784	0.00
Invested Capital Turnover	0.15	0.16	0.15	0.17	0.17	0.31	0.00
Increase / (Decrease) in Invested Capital	1,030	627	-238	1,499	1,291	11,784	0.00
Enterprise Value (EV)	23,978	24,661	31,341	31,389	26,108	10,816	0.00
Market Capitalization	15,030	16,276	22,687	22,649	17,894	1,855	1,855
Book Value per Share	$11.79	$10.92	$9.27	$9.51	$12.42	$40.33	$0.00
Tangible Book Value per Share	$11.79	$10.92	$9.27	$9.50	$12.34	$39.59	$0.00
Total Capital	17,955	16,220	16,642	17,345	15,712	12,380	0.00
Total Debt	7,612	6,135	7,116	7,096	5,817	6,238	0.00
Total Long-Term Debt	6,615	6,135	6,119	7,096	5,817	5,956	0.00
Net Debt	5,552	4,827	4,756	4,267	3,137	5,642	0.00
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	559	618	649	518	327	440	0.00
Debt-free Net Working Capital (DFNWC)	1,546	1,113	2,386	2,707	2,389	781	0.00
Net Working Capital (NWC)	549	1,113	1,388	2,707	2,389	499	0.00
Net Nonoperating Expense (NNE)	-38	-208	77	190	-107	162	-153
Net Nonoperating Obligations (NNO)	5,650	4,879	4,811	4,325	3,179	5,642	0.00
Total Depreciation and Amortization (D&A)	0.00	0.00	5.67	23	23	24	33
Debt-free, Cash-free Net Working Capital to Revenue	24.70%	26.23%	29.02%	22.63%	15.41%	24.25%	0.00%
Debt-free Net Working Capital to Revenue	68.31%	47.26%	106.63%	118.24%	112.56%	43.03%	0.00%
Net Working Capital to Revenue	24.23%	47.26%	62.05%	118.24%	112.56%	27.49%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.92	$2.54	$0.10	$1.49	$1.32	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	448.19M	447.60M	437.96M	414.79M	375.44M	0.00	0.00
Adjusted Diluted Earnings per Share	$1.91	$2.53	$0.10	$1.49	$1.32	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	594.11M	602.90M	437.97M	414.80M	375.46M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	576.45M	597.43M	607.22M	607.18M	607.11M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	905	1,045	646	1,002	1,162	1,836	955
Normalized NOPAT Margin	39.97%	44.36%	28.88%	43.74%	54.77%	101.21%	53.21%
Pre Tax Income Margin	58.79%	72.20%	10.28%	54.21%	80.19%	135.67%	84.57%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	6.56	9.54	1.86	8.27	11.37	10.20	6.36
NOPAT to Interest Expense	5.73	7.97	1.63	8.61	10.16	9.77	4.87
EBIT Less CapEx to Interest Expense	6.56	9.54	1.86	8.27	11.37	10.20	6.36
NOPAT Less CapEx to Interest Expense	5.73	7.97	1.63	8.61	10.16	9.77	4.87
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	64.92%	50.28%	413.23%	74.01%	65.98%	36.29%	71.35%
Augmented Payout Ratio	82.17%	68.21%	413.23%	74.01%	65.98%	36.47%	71.35%

This table displays calculated financial ratios and metrics derived from Royalty Pharma's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.05%	-0.41%	5.29%	-0.17%	-16.96%	5.36%	-6.48%	0.42%	21.69%	-1.73%	-2.10%
EBITDA Growth	930.09%	-52.59%	463.69%	-38.86%	-90.75%	226.33%	-41.59%	-29.13%	195.35%	-548.40%	-0.12%
EBIT Growth	930.09%	-52.59%	463.69%	-38.86%	-90.75%	226.33%	-41.59%	-29.13%	205.49%	-568.70%	2.19%
NOPAT Growth	1,134.40%	-41.02%	385.38%	8.35%	-110.78%	281.41%	-21.21%	-34.13%	117.99%	-320.22%	-36.58%
Net Income Growth	10,243.53%	-53.41%	560.53%	-44.67%	-100.84%	217.63%	-44.61%	-28.53%	297.47%	-1,236.61%	-0.62%
EPS Growth	5,400.00%	-58.56%	656.25%	-54.00%	-98.68%	206.73%	-50.00%	-28.57%	533.33%	-10,300.00%	33.33%
Operating Cash Flow Growth	-10.32%	-3.90%	22.68%	8.29%	-35.71%	35.57%	6.44%	5.72%	124.62%	16.32%	14.70%
Free Cash Flow Firm Growth	-1,963.89%	-4,623.87%	-182.22%	-154.30%	-110.83%	85.88%	496.77%	222.56%	148.75%	92.56%	78.46%
Invested Capital Growth	10.13%	6.88%	13.11%	3.81%	-0.05%	4.37%	-7.84%	-1.70%	0.48%	-1.63%	3.61%
Revenue Q/Q Growth	-4.28%	5.13%	5.10%	-5.41%	-4.71%	11.14%	-0.35%	-21.31%	20.90%	-1.35%	7.00%
EBITDA Q/Q Growth	33.81%	-57.46%	270.10%	388.97%	-93.84%	405.73%	-59.86%	-26.02%	184.11%	-333.85%	-51.30%
EBIT Q/Q Growth	33.81%	-57.46%	270.10%	388.97%	-93.84%	405.73%	-59.86%	-26.02%	184.11%	-333.85%	-51.30%
NOPAT Q/Q Growth	47.76%	-50.82%	172.62%	622.12%	-108.43%	304.71%	-39.14%	-48.05%	241.77%	-275.78%	-49.12%
Net Income Q/Q Growth	29.63%	-58.54%	314.84%	4,648.96%	-100.60%	487.81%	-65.25%	-30.99%	183.45%	-376.77%	-55.16%
EPS Q/Q Growth	19.57%	-61.98%	426.09%	2,200.00%	-99.10%	593.75%	-68.00%	-34.21%	173.08%	-425.00%	-54.29%
Operating Cash Flow Q/Q Growth	-19.72%	5.53%	6.90%	-0.97%	-13.98%	34.72%	-5.64%	-41.21%	81.40%	5.77%	-6.28%
Free Cash Flow Firm Q/Q Growth	-37.15%	39.64%	-314.32%	-501.73%	-213.91%	-101.05%	173.65%	20.01%	509.33%	70.48%	15.48%
Invested Capital Q/Q Growth	-1.39%	0.60%	8.70%	2.13%	-4.30%	6.46%	-0.23%	-1.67%	-0.06%	-6.00%	6.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	84.64%	60.55%	149.63%	42.49%	8.22%	127.18%	27.95%	69.38%	73.79%	-106.07%	44.75%
Operating Margin	94.01%	60.90%	130.17%	50.19%	-12.99%	102.82%	28.24%	46.24%	70.03%	-85.31%	33.52%
EBIT Margin	84.64%	60.55%	149.63%	42.49%	8.22%	127.18%	27.95%	69.38%	73.79%	-106.07%	44.75%
Profit (Net Income) Margin	76.28%	56.32%	142.80%	36.18%	-0.75%	120.39%	22.76%	65.28%	74.43%	-107.83%	38.44%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	90.12%	93.02%	95.43%	85.14%	-9.15%	94.66%	81.44%	94.09%	100.86%	101.66%	85.90%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	14.15%	8.91%	19.70%	7.82%	-1.42%	16.53%	4.48%	7.68%	11.56%	-9.24%	5.03%
ROIC Less NNEP Spread (ROIC-NNEP)	12.21%	8.39%	21.11%	6.18%	-0.36%	18.69%	3.85%	10.18%	12.26%	-15.20%	5.64%
Return on Net Nonoperating Assets (RNNOA)	6.49%	4.32%	10.75%	2.89%	-0.17%	9.23%	1.79%	4.13%	5.29%	-7.02%	2.49%
Return on Equity (ROE)	20.63%	13.23%	30.45%	10.71%	-1.59%	25.76%	6.27%	11.81%	16.85%	-16.27%	7.51%
Cash Return on Invested Capital (CROIC)	2.99%	1.70%	-1.99%	2.95%	6.61%	5.91%	10.86%	4.79%	3.48%	3.77%	2.75%
Operating Return on Assets (OROA)	11.36%	7.92%	20.01%	5.47%	1.11%	18.04%	3.88%	9.40%	10.11%	-13.82%	5.68%
Return on Assets (ROA)	10.24%	7.37%	19.09%	4.66%	-0.10%	17.08%	3.16%	8.84%	10.19%	-14.05%	4.88%
Return on Common Equity (ROCE)	13.85%	8.73%	19.96%	6.98%	-1.00%	15.97%	3.85%	7.19%	9.90%	-9.38%	4.31%
Return on Equity Simple (ROE_SIMPLE)	26.44%	0.00%	24.95%	15.90%	18.26%	0.00%	6.07%	7.50%	10.26%	0.00%	14.53%
Net Operating Profit after Tax (NOPAT)	534	362	735	270	-52	613	151	249	479	-338	192
NOPAT Margin	94.01%	60.90%	130.17%	50.19%	-9.09%	102.82%	28.24%	46.24%	70.03%	-59.72%	33.52%
Net Nonoperating Expense Percent (NNEP)	1.93%	0.52%	-1.41%	1.65%	-1.06%	-2.16%	0.63%	-2.50%	-0.70%	5.96%	-0.62%
Return On Investment Capital (ROIC_SIMPLE)	3.07%	2.01%	-	-	-	3.78%	-	-	-	-2.03%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	19.48%	11.39%	10.04%	10.18%	10.15%	9.93%	10.67%	8.85%	12.53%	12.94%	8.84%
R&D to Revenue	8.89%	0.08%	0.09%	0.09%	0.09%	0.08%	9.42%	0.09%	0.07%	8.93%	4.45%
Operating Expenses to Revenue	5.99%	39.10%	-30.17%	49.81%	112.99%	-2.82%	71.76%	53.76%	29.97%	185.31%	66.48%
Earnings before Interest and Taxes (EBIT)	481	359	845	228	47	758	150	373	505	-600	257
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	481	359	845	228	47	758	150	373	505	-600	257
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.68	2.16	2.44	2.41	2.75	2.49	2.58	2.86	3.52	4.03	3.76
Price to Tangible Book Value (P/TBV)	2.68	2.16	2.44	2.41	2.75	2.49	2.58	2.86	3.52	4.03	3.76
Price to Revenue (P/Rev)	7.93	6.64	7.41	6.99	7.98	6.91	6.82	7.62	8.89	10.14	10.30
Price to Earnings (P/E)	16.42	17.50	14.66	23.22	22.37	14.34	85.97	70.58	63.18	529.67	45.68
Dividend Yield	2.73%	3.29%	2.93%	3.13%	2.71%	2.94%	3.00%	2.63%	2.23%	2.03%	1.94%
Earnings Yield	6.09%	5.72%	6.82%	4.31%	4.47%	6.97%	1.16%	1.42%	1.58%	0.19%	2.19%
Enterprise Value to Invested Capital (EV/IC)	1.71	1.50	1.62	1.62	1.79	1.65	1.69	1.83	2.05	2.19	2.11
Enterprise Value to Revenue (EV/Rev)	11.93	10.59	11.38	10.60	11.47	10.47	10.22	10.90	12.43	14.01	14.35
Enterprise Value to EBITDA (EV/EBITDA)	14.11	16.21	13.73	20.06	19.34	13.81	55.51	48.15	42.61	88.45	29.62
Enterprise Value to EBIT (EV/EBIT)	14.11	16.21	13.73	20.06	19.34	13.81	55.51	48.15	42.61	89.89	29.94
Enterprise Value to NOPAT (EV/NOPAT)	14.21	18.55	16.70	24.71	27.33	16.53	59.90	58.87	51.78	102.07	34.18
Enterprise Value to Operating Cash Flow (EV/OCF)	10.00	8.66	9.21	8.89	9.81	8.25	8.53	9.36	10.79	14.62	15.62
Enterprise Value to Free Cash Flow (EV/FCFF)	60.05	91.28	0.00	56.04	27.13	28.51	14.93	37.83	58.96	57.53	78.33
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.78	0.74	0.74	0.78	0.62	0.61	0.64	0.73	0.73	0.75	0.68
Long-Term Debt to Equity	0.68	0.64	0.64	0.78	0.62	0.61	0.64	0.62	0.62	0.64	0.59
Financial Leverage	0.53	0.52	0.51	0.47	0.46	0.49	0.47	0.41	0.43	0.46	0.44
Leverage Ratio	1.72	1.69	1.71	1.78	1.69	1.69	1.68	1.72	1.73	1.74	1.70
Compound Leverage Factor	1.55	1.58	1.63	1.51	-0.15	1.60	1.37	1.62	1.74	1.76	1.46
Debt to Total Capital	43.76%	42.40%	42.58%	43.81%	38.36%	37.83%	39.01%	42.07%	42.03%	42.76%	40.57%
Short-Term Debt to Total Capital	5.74%	5.56%	5.58%	0.00%	0.00%	0.00%	0.00%	5.90%	5.89%	5.99%	5.69%
Long-Term Debt to Total Capital	38.03%	36.84%	37.00%	43.81%	38.36%	37.83%	39.01%	36.17%	36.14%	36.77%	34.89%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	17.81%	18.91%	18.97%	18.88%	21.02%	21.94%	21.93%	20.85%	22.83%	23.42%	24.33%
Common Equity to Total Capital	38.43%	38.69%	38.45%	37.32%	40.62%	40.24%	39.06%	37.08%	35.14%	33.82%	35.10%
Debt to EBITDA	3.98	5.15	4.05	6.43	4.62	3.44	14.33	13.33	10.35	20.08	6.53
Net Debt to EBITDA	3.12	3.75	2.98	4.07	3.35	2.70	10.42	7.89	6.53	13.42	4.43
Long-Term Debt to EBITDA	3.46	4.47	3.52	6.43	4.62	3.44	14.33	11.46	8.90	17.27	5.62
Debt to NOPAT	4.01	5.89	4.93	7.92	6.54	4.11	15.46	16.29	12.57	23.18	7.54
Net Debt to NOPAT	3.14	4.30	3.63	5.02	4.73	3.23	11.24	9.65	7.93	15.49	5.11
Long-Term Debt to NOPAT	3.48	5.12	4.28	7.92	6.54	4.11	15.46	14.01	10.81	19.93	6.48
Altman Z-Score	1.84	1.59	1.83	1.70	2.18	2.14	2.00	2.00	2.26	2.15	2.37
Noncontrolling Interest Sharing Ratio	32.89%	34.04%	34.44%	34.79%	36.74%	38.02%	38.55%	39.13%	41.24%	42.32%	42.58%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.56	1.44	1.54	9.35	12.52	7.90	13.51	2.52	2.36	2.19	2.07
Quick Ratio	1.54	1.41	1.51	9.26	12.30	7.65	13.16	2.48	2.32	2.08	1.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-916	-668	-1,107	-267	-44	-14	1,346	492	410	-100	-339
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-14.04	-10.16	-16.65	-5.45	-1.00	-0.30	29.25	10.48	8.73	-2.13	-7.22
Operating Cash Flow to Interest Expense	9.13	11.29	10.58	13.43	15.03	16.35	12.46	12.95	22.02	12.14	11.47
Operating Cash Flow Less CapEx to Interest Expense	9.13	11.29	10.58	13.43	15.03	16.35	12.46	12.95	22.02	12.14	11.47
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.13	0.13	0.13	0.13	0.14	0.14	0.14	0.14	0.13	0.13
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	15,770	15,993	15,897	14,625	14,320	14,963	14,055	14,088	14,327	14,336	15,250
Invested Capital Turnover	0.15	0.15	0.15	0.16	0.16	0.16	0.16	0.17	0.17	0.15	0.15
Increase / (Decrease) in Invested Capital	1,451	1,030	1,842	537	-7.24	627	-1,195	-243	69	-238	532
Enterprise Value (EV)	27,007	23,978	25,778	23,726	25,678	24,661	23,758	25,746	29,325	31,341	32,238
Market Capitalization	17,945	15,030	16,789	15,634	17,871	16,276	15,854	17,994	20,965	22,687	23,153
Book Value per Share	$11.60	$11.79	$11.58	$10.84	$14.49	$10.92	$10.20	$10.35	$9.80	$9.27	$10.13
Tangible Book Value per Share	$11.60	$11.79	$11.58	$10.84	$14.49	$10.92	$10.20	$10.35	$9.80	$9.27	$10.13
Total Capital	17,406	17,955	17,866	17,354	16,003	16,220	15,716	16,940	16,943	16,642	17,528
Total Debt	7,617	7,612	7,607	7,602	6,139	6,135	6,131	7,126	7,121	7,116	7,111
Total Long-Term Debt	6,619	6,615	6,610	7,602	6,139	6,135	6,131	6,127	6,123	6,119	6,115
Net Debt	5,962	5,552	5,601	4,817	4,443	4,827	4,458	4,220	4,492	4,756	4,821
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	559	559	625	500	563	618	659	603	535	649	666
Debt-free Net Working Capital (DFNWC)	1,659	1,546	1,623	2,303	1,435	1,113	1,601	2,781	2,513	2,386	2,207
Net Working Capital (NWC)	660	549	626	2,303	1,435	1,113	1,601	1,781	1,514	1,388	1,210
Net Nonoperating Expense (NNE)	101	27	-71	75	-47	-105	29	-102	-30	272	-28
Net Nonoperating Obligations (NNO)	5,982	5,650	5,639	4,873	4,456	4,879	4,470	4,274	4,505	4,811	4,834
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	24.70%	24.70%	27.57%	22.36%	25.16%	26.23%	28.35%	25.52%	22.66%	29.02%	29.65%
Debt-free Net Working Capital to Revenue	73.28%	68.31%	71.64%	102.94%	64.11%	47.26%	68.87%	117.76%	106.51%	106.63%	98.22%
Net Working Capital to Revenue	29.17%	24.23%	27.65%	102.94%	64.11%	47.26%	68.87%	75.44%	64.19%	62.05%	53.87%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.55	$0.46	$1.22	$0.23	$0.01	$1.11	$0.16	$0.51	$0.76	($1.04)	$0.32
Adjusted Weighted Average Basic Shares Outstanding	435.48M	448.19M	447.63M	451.02M	448.62M	447.60M	448.44M	450.41M	445.61M	437.96M	439.29M
Adjusted Diluted Earnings per Share	$0.55	$0.46	$1.21	$0.23	$0.01	$1.11	$0.16	$0.50	$0.76	($1.04)	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	578.10M	594.11M	592.73M	596.91M	597.48M	602.90M	601.14M	605.86M	607.25M	437.97M	607.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	562.24M	576.45M	589.18M	593.46M	597.44M	597.43M	597.43M	601.82M	607.14M	607.22M	607.22M
Normalized Net Operating Profit after Tax (NOPAT)	374	253	515	189	-52	429	106	174	335	-338	135
Normalized NOPAT Margin	65.80%	42.63%	91.12%	35.13%	-9.09%	71.98%	19.77%	32.36%	49.02%	-59.72%	23.46%
Pre Tax Income Margin	76.28%	56.32%	142.80%	36.18%	-0.75%	120.39%	22.76%	65.28%	74.43%	-107.83%	38.44%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.37	5.47	12.70	4.66	1.06	16.04	3.26	7.95	10.75	-12.78	5.46
NOPAT to Interest Expense	8.19	5.50	11.05	5.50	-1.17	12.97	3.29	5.30	10.20	-7.20	4.09
EBIT Less CapEx to Interest Expense	7.37	5.47	12.70	4.66	1.06	16.04	3.26	7.95	10.75	-12.78	5.46
NOPAT Less CapEx to Interest Expense	8.19	5.50	11.05	5.50	-1.17	12.97	3.29	5.30	10.20	-7.20	4.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	50.00%	64.92%	50.60%	83.82%	71.99%	50.28%	169.03%	157.32%	154.07%	413.23%	101.71%
Augmented Payout Ratio	103.07%	82.17%	62.69%	108.13%	71.99%	68.21%	242.74%	185.87%	154.07%	413.23%	101.71%

Frequently Asked Questions About Royalty Pharma's Financials

When does Royalty Pharma's financial year end?

According to the most recent income statement we have on file, Royalty Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Royalty Pharma's net income changed over the last 6 years?

Royalty Pharma's net income appears to be on a downward trend, with a most recent value of $1.33 billion in 2024, falling from $1.52 billion in 2018. The previous period was $1.70 billion in 2023. View Royalty Pharma's forecast to see where analysts expect Royalty Pharma to go next.

What is Royalty Pharma's operating income?

Royalty Pharma's total operating income in 2024 was $1.29 billion, based on the following breakdown:

Total Gross Profit: $2.26 billion
Total Operating Expenses: $971.13 million

How has Royalty Pharma revenue changed over the last 6 years?

Over the last 6 years, Royalty Pharma's total revenue changed from $1.79 billion in 2018 to $2.26 billion in 2024, a change of 26.1%.

How much debt does Royalty Pharma have?

Royalty Pharma's total liabilities were at $7.88 billion at the end of 2024, a 25.1% increase from 2023, and a 24.9% increase since 2019.

How much cash does Royalty Pharma have?

In the past 5 years, Royalty Pharma's cash and equivalents has ranged from $246.20 million in 2019 to $1.71 billion in 2022, and is currently $929.03 million as of their latest financial filing in 2024.

How has Royalty Pharma's book value per share changed over the last 6 years?

Over the last 6 years, Royalty Pharma's book value per share changed from 0.00 in 2018 to 11.79 in 2024, a change of 1,179.0%.

Related Companies

This page (NASDAQ:RPRX) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Financials

Frequently Asked Questions About Royalty Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Financials

Annual Income Statements for Royalty Pharma

Quarterly Income Statements for Royalty Pharma

Annual Cash Flow Statements for Royalty Pharma

Quarterly Cash Flow Statements for Royalty Pharma

Annual Balance Sheets for Royalty Pharma

Quarterly Balance Sheets for Royalty Pharma

Annual Metrics And Ratios for Royalty Pharma

Quarterly Metrics And Ratios for Royalty Pharma

Frequently Asked Questions About Royalty Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools